Stroke Prevention in Atrial Fibrillation
Description:
The value of the stroke prevention in atrial fibrillation (SPAF) market is expected to grow rapidly as novel oral anticoagulant (NOAC) class molecules secure approvals of their antidotes and physician acceptance of these drugs rises. This report addresses the following questions:
Which patient subgroups and markets will have the largest impact on SPAF sales? -How will the approval of antidotes affect uptake of the NOAC class 
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